Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Precipio to Effect 1-for-15 Reverse Stock Split

Precipio to Effect 1-for-15 Reverse Stock Split

Apr 26, 2019
|
staff reporter

NEW YORK (GenomeWeb) — Cancer diagnostics developer Precipio said today that it will implement a 1-for-15 reverse stock split in a bid to regain compliance with a Nasdaq listing requirements.

In a filing with the US Securities and Exchange Commission, New Haven, Connecticut-based firm said that it received notice late last month that it did not meet the exchange's $1 minimum bid price requirement and that its stock was facing delisting.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Not Taking the Post

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

Threats Over WHO Funding

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

Sales Stopped

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

Nature Papers Examine Single-Cell RNA Sequencing Protocols, Describe New Labeling Approach

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Molecular Diagnostics

  1. T2 Biosystems Receives Nasdaq Warning Letter

  2. FDA Grants Emergency Use Authorization for BD Coronavirus Test Kit

  3. BillionToOne Developing Coronavirus Dx Test Based on Sanger Sequencing

  4. HHS Releases Guidance Allowing Pharmacists to Offer SARS-CoV-2 Tests

  5. Qiagen Reports Preliminary Q1 Revenue Growth of 9 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.